Global Lung Cancer Diagnostics Market Size Set for Rapid Growth, to...

Global Lung Cancer Diagnostics Market Size Set for Rapid Growth, to reach Value $26.26 Billion by 2032

Postado 2024-12-13 09:02:14

Global lung cancer diagnostics market size earned around $13.99 Billion in 2023 and is expected to reach $26.26 Billion by 2032, with a projected CAGR of 7.25%

Zion Market Research has published a new report titled “Lung Cancer Diagnostics Market by Type (Non-small Cell Lung Cancer and Small Cell Lung Cancer) and Test (Biopsy, Imaging Test, Molecular Test, Sputum Cytology, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2024– 2032”

Request Free Sample

Lung cancer is a type of cancer which starts in the lungs. Lungs execute a vital task of taking in oxygen and discharging carbon dioxide. Lung cancer is the predominant cause of cancer demises worldwide. Cigarette smoking is a key factor that can lead to lung cancer. Passive smoking also leads to development of lung cancer in non-smokers. Other causes of lung cancer are exposure to asbestos fibers and radon gas. Non-small cell lung cancer and small cell lung cancer are the two types of lung cancer. As per statistics from the American Cancer Society, there will be about 228,000 new cases of lung cancer in the U.S. in 2019. Tests like chest x-ray, CT scan, MRI, PET scan, sputum cytology, bone scan, and biopsy are performed to diagnose lung cancer.

Factors such as development of biomarkers specific to lung cancer, high number of awareness programs undertaken by government and non-governmental organizations, efforts taken to increase the diagnosis and screening rates of lung cancer, heavy use of tobacco in some regions, and technological advancements will act as major driving factors in the growth of global lung cancer diagnostics market. Strong pipeline of biomarkers and favorable government policies in developing regions will act as an opportunity for the market players in the lung cancer diagnostics market. Nonetheless, dearth of skilled personnel, and lack of awareness regarding early screening of lung cancer in low income countries will restrict the growth of global lung cancer diagnostics market.

The global lung cancer diagnostics market has been split into type, test. Based on type, lung cancer diagnostics market has been segmented into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment accounted for the highest market share in 2018 due to accessibility of new lung cancer diagnostics that enable the detection of big tumor developments.

The test segment has been segmented into biopsy, imaging test, molecular test, sputum cytology, and others. The imaging test segment accounted for the highest market share in 2018 due to repeated use of imaging techniques like x-ray, CT, and MRI.

Request Customization

The geographical segmentation comprises the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America will be the leading region during the forecast period. Development of technology-enabled diagnostics, presence of leading market players, and rapid uptake of new technologies will boost the market growth in this region. Europe will be the second largest market. The key reasons are existence of skilled researchers, increase in awareness about early screening of lung cancer, and favorable reimbursement scenario. Asia Pacific will propagate at speedy rate over the forecast period due to increasing cases of lung cancer due to heavy use of tobacco and efforts taken by various agencies to create awareness regarding early diagnosis of lung cancer. Latin America market will develop at a significant rate during the forecast period. The Africa and Middle Eastern countries are likely to experience perceptible growth in the estimated time-frame.

Buy Now

The report also includes detailed profiles of key players such as

Roche Diagnostics
bioMérieux
Thermo Fisher Scientific
Illumina Inc.
Qiagen N.V.
Agilent Technologies
Sanofi S.A.
AstraZeneca plc
and Janssen

This report segments the Global Lung Cancer Diagnostics Market as follows:

Global Lung Cancer Diagnostics Market: By Type

Non-small Cell Lung Cancer
Small Cell Lung Cancer

Global Lung Cancer Diagnostics Market: By Test

Biopsy
Imaging Test
Molecular Test
Sputum Cytology
Others

Global Lung Cancer Diagnostics Market: By Region

North AmericaU.S.
EuropeUKFranceGermany
Asia PacificChinaJapanIndia
Latin AmericaBrazil
Middle East and Africa